Pharsight

Namenda Xr patents expiration

NAMENDA XR's oppositions filed in EPO
NAMENDA XR IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5061703 ABBVIE Adamantane derivatives in the prevention and treatment of cerebral ischemia
Apr, 2015

(9 years ago)

US5061703

(Pediatric)

ABBVIE Adamantane derivatives in the prevention and treatment of cerebral ischemia
Oct, 2015

(8 years ago)

US8173708 ABBVIE Method and composition for administering an NMDA receptor antagonist to a subject
Nov, 2025

(1 year, 5 months from now)

US8283379 ABBVIE Methods and compositions for the treatment of CNS-related conditions
Nov, 2025

(1 year, 5 months from now)

US8362085 ABBVIE Method for administering an NMDA receptor antagonist to a subject
Nov, 2025

(1 year, 5 months from now)

US8168209 ABBVIE Method and composition for administering an NMDA receptor antagonist to a subject
Nov, 2025

(1 year, 5 months from now)

US8329752 ABBVIE Composition for administering an NMDA receptor antagonist to a subject
Nov, 2025

(1 year, 5 months from now)

US8598233 ABBVIE Method for administering an NMDA receptor antagonist to a subject
Nov, 2025

(1 year, 5 months from now)

US8283379

(Pediatric)

ABBVIE Methods and compositions for the treatment of CNS-related conditions
May, 2026

(1 year, 11 months from now)

US8329752

(Pediatric)

ABBVIE Composition for administering an NMDA receptor antagonist to a subject
May, 2026

(1 year, 11 months from now)

US8598233

(Pediatric)

ABBVIE Method for administering an NMDA receptor antagonist to a subject
May, 2026

(1 year, 11 months from now)

US8168209

(Pediatric)

ABBVIE Method and composition for administering an NMDA receptor antagonist to a subject
May, 2026

(1 year, 11 months from now)

US8173708

(Pediatric)

ABBVIE Method and composition for administering an NMDA receptor antagonist to a subject
May, 2026

(1 year, 11 months from now)

US8362085

(Pediatric)

ABBVIE Method for administering an NMDA receptor antagonist to a subject
May, 2026

(1 year, 11 months from now)

US8039009 ABBVIE Modified release formulations of memantine oral dosage forms
Mar, 2029

(4 years from now)

US8039009

(Pediatric)

ABBVIE Modified release formulations of memantine oral dosage forms
Sep, 2029

(5 years from now)

Namenda Xr is owned by Abbvie.

Namenda Xr contains Memantine Hydrochloride.

Namenda Xr has a total of 16 drug patents out of which 2 drug patents have expired.

Expired drug patents of Namenda Xr are:

  • US5061703
  • US5061703*PED

Namenda Xr was authorised for market use on 21 June, 2010.

Namenda Xr is available in capsule, extended release;oral dosage forms.

Namenda Xr can be used as treatment of moderate to severe dementia of the alzheimer's type.

The generics of Namenda Xr are possible to be released after 24 September, 2029.

Drug Exclusivity Drug Exclusivity Expiration
M(M-138) Jul 03, 2017
Pediatric Exclusivity(PED) Jan 03, 2018
New Dosage Form(NDF) Jun 21, 2013

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using MEMANTINE HYDROCHLORIDE ingredient

Market Authorisation Date: 21 June, 2010

Treatment: Treatment of moderate to severe dementia of the alzheimer's type

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

How can I launch a generic of NAMENDA XR before it's drug patent expiration?
More Information on Dosage

NAMENDA XR family patents

Family Patents